Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Knee Arthroplasty

Launched by CONSORCI SANITARI DEL MARESME · Apr 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a supplement called micronized creatine monohydrate on older adults who have had total knee replacement surgery. The goal is to see if taking creatine can help improve muscle mass, strength, and overall physical performance during recovery. Participants in the study will take creatine daily for 12 weeks, starting with a higher dose for the first week and then a lower dose for the rest of the trial.

To be eligible, participants must be at least 65 years old, have recently undergone their first knee replacement surgery, and be involved in a standard rehabilitation program. However, those with certain health conditions, such as severe kidney or liver issues, specific neuromuscular diseases, or significant cognitive impairment, will not be included. Throughout the trial, researchers will measure changes in muscle strength and function at the beginning, and again at 3 and 6 months after starting the supplement. This study aims to provide valuable information about how creatine can support recovery in older adults after knee surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Persons 65 years of age or older who have been operated on for the first time for total knee arthroplasty,
• • who are undergoing an outpatient rehabilitation program according to standard clinical practice,
• • who sign the informed consent form.
• Exclusion Criteria:
• • Chronic renal disease at stage G3b or higher or glomerular filtration rate \<30 ml/min/1.73m2.
• • Hepatic insufficiency, cirrhosis.
• • Neuromuscular and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, Parkinson's disease, etc.).
• • Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD III-IV).
• • Moderate or severe chronic heart failure (NYHA 3-4).
• • Central sensitivity syndrome (fibromyalgia and chronic fatigue syndrome).
• • Moderate or severe cognitive impairment (GDS≥4).
• • Moderate-severe dependence for basic activities of daily living (preintervention Barthel index \<60 points).
• • Hemiparesis, amputation or malformation of any limb.
• • Consumption of creatine monohydrate supplements in the last 6 months.